Frazier Life Sciences Management, L.P. — MIRUM PHARMACEUTICALS INC MIRM: Quarterly 13F Position History
Frazier Life Sciences Management, L.P. has reported MIRUM PHARMACEUTICALS INC (MIRM) on 17 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2022. As of Q1 2026, the position is sized at 7,679,684 shares ($709.4M market value, 18.25% of the equity book). Quarter-over-quarter share count change: + 884,563 (+13.0%) .
- 7,679,684Shares Held (Latest Filing)
- $709.4MReported Market Value (Latest Filing)
- 18.25%Portfolio Weight (% of 13F Equity Book)
- +884,563Quarter-over-Quarter Share Change
- +$172.7MQuarter-over-Quarter Value Change
- 7,679,684Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 17 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 7,679,684 | +884,563 | +13.0% | $709.4M | 18.25% | $92.38 |
| Q4 2025 | 6,795,121 | 0 | — | $536.7M | 14.42% | $78.99 |
| Q3 2025 | 6,795,121 | 0 | — | $498.2M | 14.93% | $73.31 |
| Q2 2025 | 6,795,121 | 0 | — | $345.8M | 13.83% | $50.89 |
| Q1 2025 | 6,795,121 | +224,729 | +3.4% | $306.1M | 13.99% | $45.05 |
| Q4 2024 | 6,570,392 | 0 | — | $271.7M | 11.28% | $41.35 |
| Q3 2024 | 6,570,392 | +75,000 | +1.2% | $256.2M | 10.27% | $39.00 |
| Q2 2024 | 6,495,392 | 0 | — | $222.1M | 10.39% | $34.19 |
| Q1 2024 | 6,495,392 | 0 | — | $163.2M | 6.88% | $25.12 |
| Q4 2023 | 6,495,392 | +25,000 | +0.4% | $191.7M | 10.25% | $29.52 |
| Q3 2023 | 6,470,392 | +2,110,285 | +48.4% | $204.5M | 13.59% | $31.60 |
| Q2 2023 | 4,360,107 | +500,000 | +13.0% | $112.8M | 6.74% | $25.87 |
| Q1 2023 | 3,860,107 | 0 | — | $92.7M | 6.71% | $24.02 |
| Q4 2022 | 3,860,107 | +32,326 | +0.8% | $75.3M | 4.68% | $19.50 |
| Q3 2022 | 3,827,781 | +260,869 | +7.3% | $80.4M | 6.19% | $21.01 |
| Q2 2022 | 3,566,912 | 0 | — | $69.4M | 6.55% | $19.46 |
| Q1 2022 | 3,566,912 | — | — | $78.5M | 6.69% | $22.02 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a MIRM position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported MIRUM PHARMACEUTICALS INC (MIRM) on its 13F-HR filing for the period ending 2022-03-31 (Q1 2022). The position has appeared on 17 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in MIRM?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. added 884,563 shares of MIRM (+13.0%), bringing the total reported position to 7,679,684 shares at a market value of $709.4M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in MIRM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.